Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Oramed Pharmaceuticals (ORMP) Shares Issued (2022 - 2025)

Oramed Pharmaceuticals' Shares Issued history spans 3 years, with the latest figure at $500000.0 for Q1 2025.

  • For Q1 2025, Shares Issued changed N/A year-over-year to $500000.0; the TTM value through Sep 2025 reached $500000.0, changed N/A, while the annual FY2023 figure was $2.4 million, 1511.09% up from the prior year.
  • Shares Issued reached $500000.0 in Q1 2025 per ORMP's latest filing, up from -$2000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $3.0 million in Q1 2022 to a low of -$2.9 million in Q3 2022.
  • Average Shares Issued over 3 years is $427142.9, with a median of $20000.0 recorded in 2022.
  • The largest YoY upside for Shares Issued was 99.93% in 2023 against a maximum downside of 18.15% in 2023.
  • A 3-year view of Shares Issued shows it stood at $20000.0 in 2022, then tumbled by 110.0% to -$2000.0 in 2023, then soared by 25100.0% to $500000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Shares Issued are $500000.0 (Q1 2025), -$2000.0 (Q3 2023), and $2.4 million (Q1 2023).